Oncolytics Biotech to Sell Up to $50M in Stock
Ticker: ONCY · Form: 6-K · Filed: Aug 2, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Aug 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: at-the-market offering, capital raise, equity financing
TL;DR
Oncolytics Biotech inks ATM deal with Cantor Fitzgerald to sell up to $50M common stock.
AI Summary
On August 2, 2024, Oncolytics Biotech Inc. entered into an at-the-market sales agreement with Cantor Fitzgerald & Co. This agreement allows Oncolytics to sell up to $50 million worth of its common stock. The filing incorporates Exhibit 99.1 by reference into its Registration Statement on Form F-10.
Why It Matters
This allows Oncolytics Biotech to raise capital, potentially funding its ongoing research and development efforts for its pharmaceutical products.
Risk Assessment
Risk Level: medium — The company is entering into an at-the-market offering, which can dilute existing shareholders and indicates potential funding needs.
Key Numbers
- $50 million — ATM Offering Capacity (Maximum amount of common stock Oncolytics Biotech can sell through the agreement.)
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- Cantor Fitzgerald & Co. (company) — Sales Agent
- $50-million (dollar_amount) — Maximum offering amount
- August 2, 2024 (date) — Date of Sales Agreement
FAQ
What is the purpose of the at-the-market sales agreement?
The agreement allows Oncolytics Biotech to sell up to $50 million worth of its common stock at its discretion, providing a mechanism for capital raising.
Who is the counterparty to the sales agreement?
The sales agreement was entered into with Cantor Fitzgerald & Co.
When was the sales agreement executed?
The sales agreement was executed on August 2, 2024.
What is the maximum value of common stock that can be sold under this agreement?
The company may sell up to $50 million worth of common stock.
What is being incorporated by reference into the Registration Statement on Form F-10?
Exhibit 99.1, included with this Form 6-K, is incorporated by reference into the Registration Statement on Form F-10 of Oncolytics Biotech Inc.
Filing Stats: 267 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-08-02 17:11:26
Key Financial Figures
- $50 — scretion, from time to time, sell up to $50-million worth of common shares. On Ju
Filing Documents
- tm2420730d1_6k.htm (6-K) — 10KB
- tm2420730d1_ex99-1.htm (EX-99.1) — 287KB
- 0001104659-24-085447.txt ( ) — 298KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) Date: August 2, 2024 By: /s/ Kirk Look Kirk Look Chief Financial Officer